116 related articles for article (PubMed ID: 11904459)
1. Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas.
Dai H; Holm R; Kristensen GB; Abeler VM; Børresen-Dale AL; Helland A
Anal Cell Pathol; 2001; 23(2):45-9. PubMed ID: 11904459
[TBL] [Abstract][Full Text] [Related]
2. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
[TBL] [Abstract][Full Text] [Related]
3. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
van Rhijn BW; van Tilborg AA; Lurkin I; Bonaventure J; de Vries A; Thiery JP; van der Kwast TH; Zwarthoff EC; Radvanyi F
Eur J Hum Genet; 2002 Dec; 10(12):819-24. PubMed ID: 12461689
[TBL] [Abstract][Full Text] [Related]
4. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.
Sibley K; Stern P; Knowles MA
Oncogene; 2001 Jul; 20(32):4416-8. PubMed ID: 11466624
[TBL] [Abstract][Full Text] [Related]
5. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
6. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.
Cappellen D; De Oliveira C; Ricol D; de Medina S; Bourdin J; Sastre-Garau X; Chopin D; Thiery JP; Radvanyi F
Nat Genet; 1999 Sep; 23(1):18-20. PubMed ID: 10471491
[No Abstract] [Full Text] [Related]
7. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
[TBL] [Abstract][Full Text] [Related]
8. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.
Kimura T; Suzuki H; Ohashi T; Asano K; Kiyota H; Eto Y
Cancer; 2001 Nov; 92(10):2555-61. PubMed ID: 11745189
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous cell carcinomas.
Shotelersuk V; Ittiwut C; Shotelersuk K; Triratanachat S; Poovorawan Y; Mutirangura A
Oncol Rep; 2001; 8(6):1301-4. PubMed ID: 11605053
[TBL] [Abstract][Full Text] [Related]
10. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
[TBL] [Abstract][Full Text] [Related]
11. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
12. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX
Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data.
Tsai FJ; Tsai CH; Chang JG; Wu JY
Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885
[No Abstract] [Full Text] [Related]
14. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
15. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
16. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
17. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer.
Naimi B; Latil A; Berthon P; Cussenot O
Int J Cancer; 2000 Aug; 87(3):455-6. PubMed ID: 10897055
[No Abstract] [Full Text] [Related]
18. Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma.
Wakulich C; Jackson-Boeters L; Daley TD; Wysocki GP
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 May; 93(5):573-9. PubMed ID: 12075207
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
20. Achondroplasia in Sweden caused by the G1138A mutation in FGFR3.
Alderborn A; Anvret M; Gustavson KH; Hagenäs L; Wadelius C
Acta Paediatr; 1996 Dec; 85(12):1506-7. PubMed ID: 9001669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]